Company intelligence / Profile preview

Diabetology

Ownership: Private
Development stage: Other

Overview

Diabetology Limited has developed proprietary oral delivery technologies enabling the administration of insulin and other protein/peptide drugs via the oral route. This approach aims to improve convenience, reduce complications associated with injectable therapies, and enhance patient quality of life. The company’s lead programs are focused on diabetes and obesity. Early human results have demonstrated positive outcomes for their oral insulin technology.

Therapeutic areas: Endocrinology
Modalities: Small moleculeProteinPeptides
Industry: Biotech

Drug pipeline

4 assets

Capsuglutide

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Some therapeutics previously partnered with major multinational pharmaceutical companies; current partnerships not specified

Beyond the preview

Go deeper on Diabetology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabetology.

Explore the full profile